Oracle to buy Phase Forward Inc

Oracle said it would pay $17 per share in cash for Phase Forward, a 30 per cent premium over Thursday’s closing price of $13.08.

Phase Forward is the top maker of programmes for managing clinical trials, ahead of Medidata Solutions Inc and Oracle.

Liked the story?

  • 0

    Happy
  • 0

    Amused
  • 0

    Sad
  • 0

    Frustrated
  • 0

    Angry